MLND News and Press, Millendo Therapeutics From 04/04/21

Will These Penny Stocks Keep Climbing In April? Penny stocks are starting to heat up again. The last few weeks were touch and go as markets tried to figure out which direction they wanted to head. Concerns over inflation and rates combated by upbeat sentiment about stimulus and the reop...

Gainers: Humanigen (HGEN) +81%.Universe Pharmaceuticals (UPC) +70%.SeaChange International (SEAC) +60%.Elite Education Group International (EEIQ) +34%.Cyanotech (CYAN) +34%.Fly Leasing (FLY) +27%.Trinity Biotech (TRIB) +25%.Virpax Pharmaceuticals (VRPX) +21%.Hall of Fame Resort & Ent...

Millendo Therapeutics (MLND) and privately-held Tempest Therapeutics have inked an agreement under which Millendo will merge with Tempest in an all-stock transaction.Millendo and pre-merger Tempest stockholders will own ~18.5% and ~81.5% of the combined company, respectively.Upon closing...

Orphazyme (ORPH) -31% announces topline results from pivotal trial of Arimoclomol for inclusion Body Myositis.ToughBuilt Industries (TBLT) -17% on FY earnings release.Millendo Therapeutics (MLND) -17% after announces proposed merger agreement with Tempest Th...

– Transaction to advance Tempest’s targeted oncology pipeline – - Concurrent $30M PIPE financing expected to close with merger - - Companies to host conference call today at 8:30 a.m. ET - Tempest Therapeutics, Inc. (“Tempestȁ...

Millendo Therapeutics ([[MLND]] +1.6%) announces board approval for a corporate restructuring plan which will result in an up to 85% reduction in the company's workforce.The company said that majority of the job cuts will be completed by April 15, 2021, and added that it expects to provi...

Based on an analysis of data from the ongoing Phase 1 study evaluating Millendo Therapeutics' ([[MLND]] -18.7%) MLE-301 for menopausal vasomotor symptoms, the board of directors have decided to discontinue further investment in this selective neurokinin 3 receptor antagonist candidate.While M...

Gainers: Synthetic Biologics (SYN) +141%.Helius Medical Technologies (HSDT) +91%.The Peck Company (PECK) +79%.Atomera (ATOM) +50%.Check-Cap (CHEK) +49%.Naked Brand Group (NAKD) +42%.The9 (NCTY) +37%.Gritstone Oncology (GRTS) +36%.Boston Private Financial (BPFH) +31%.Jaguar Heal...

Gainers: Synthetic Biologics (SYN) +149%, Check-Cap (CHEK) +59%, Jaguar Health (JAGX) +50%, Cyclo Therapeutics CYTH +36%, Zomedica (ZOM) +42%.Losers: Bionano Genomics BNGO -29%, Mersana Therapeutics (MRSN) -23%, Millendo Therapeutics...

– Further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, not planned following initial review of data from Phase 1 clinical study – – Company exploring expanded range of strategic alternatives to maximize its assets – ...